Rocci M L, Kosoglou T, Ferguson R K, Vlasses P H
Division of Clinical Pharmacology, Jefferson Medical College, Philadelphia, Pennsylvania.
J Pharmacol Exp Ther. 1989 Mar;248(3):923-8.
Ranitidine, procainamide and its active N-acetyl metabolite (NAPA) are renally secreted bases which can compete for carrier-mediated transport processes. The effect of ranitidine on the disposition of procainamide and NAPA was evaluated in 13 healthy men. Subjects were randomized to receive p.o. procainamide (1000 mg) alone (base line) and after p.o. ranitidine, 150 mg twice a day for 4 days. Blood and urine samples were collected at frequent intervals for 24 hr after the procainamide dose. There were no significant differences in the mean pharmacokinetic parameters of procainamide and NAPA after ranitidine coadministration compared to base line. However, individual changes did occur and regression analysis revealed a correlation between base-line procainamide renal clearance (CLR) and the change (delta) in CLR after ranitidine (r = 0.69, P less than .01). Subsequently, individuals were separated into Group I (n = 7) if they had a decrease or Group II (n = 6) if they had an increase in procainamide CLR after ranitidine. Mean +/- S.D. base-line procainamide CLR was 539 +/- 114 ml/min for Group I vs. 410 +/- 61 ml/min for Group II (P less than .01). During ranitidine coadministration, Group I had a 23% decrease in mean procainamide CLR (P less than .05), whereas Group II had a 21% increase (P less than .05). There were no significant differences in the metabolic clearance (CLM) of procainamide between the two groups at base line. However, Group I had a 45% increase (P less than .01) whereas Group II had a 41% decrease (P less than .05) in mean procainamide CLM with concomitant ranitidine.(ABSTRACT TRUNCATED AT 250 WORDS)
雷尼替丁、普鲁卡因胺及其活性N - 乙酰代谢物(NAPA)是经肾脏分泌的碱,它们可竞争载体介导的转运过程。在13名健康男性中评估了雷尼替丁对普鲁卡因胺和NAPA处置的影响。受试者被随机分组,分别口服单独的普鲁卡因胺(1000毫克)(基线)以及在口服雷尼替丁(150毫克,每日两次,共4天)后口服普鲁卡因胺。在给予普鲁卡因胺剂量后24小时内频繁采集血液和尿液样本。与基线相比,雷尼替丁联合给药后普鲁卡因胺和NAPA的平均药代动力学参数无显著差异。然而,个体变化确实发生了,回归分析显示基线普鲁卡因胺肾清除率(CLR)与雷尼替丁给药后CLR的变化(delta)之间存在相关性(r = 0.69,P小于0.01)。随后,如果雷尼替丁给药后普鲁卡因胺CLR降低,则将个体分为第一组(n = 7);如果升高,则分为第二组(n = 6)。第一组基线普鲁卡因胺CLR的平均值±标准差为539±114毫升/分钟,第二组为410±61毫升/分钟(P小于0.01)。在雷尼替丁联合给药期间,第一组普鲁卡因胺平均CLR降低了23%(P小于0.05),而第二组增加了21%(P小于0.05)。两组在基线时普鲁卡因胺的代谢清除率(CLM)无显著差异。然而,联合使用雷尼替丁时,第一组普鲁卡因胺平均CLM增加了45%(P小于0.01),而第二组降低了41%(P小于0.05)。(摘要截断于250字)